Imexpharm Corp
VN:IMP

Watchlist Manager

Imexpharm Corp

VN:IMP

Watchlist

Dividends

Discount Rate

Price: 41 350 VND -0.12% Market Closed

Market Cap: 6.4T VND

Have any thoughts about
Imexpharm Corp?

Write Note

Write Note Create Alert Ask AI

Add Note Why Create Notes?

Capture your thoughts

Note Buy Sell Hold Pass

US		Fubotv Inc NYSE:FUBO	Media
US		Bank of America Corp NYSE:BAC	Banking
US		Palantir Technologies Inc NYSE:PLTR	Technology
US	C	C3.ai Inc NYSE:AI	Technology
US		Uber Technologies Inc NYSE:UBER	Road & Rail
CN		NIO Inc NYSE:NIO	Automobiles
US		Fluor Corp NYSE:FLR	Construction
US		Jacobs Engineering Group Inc NYSE:J	Professional Services
US		TopBuild Corp NYSE:BLD	Consumer products
US		Abbott Laboratories NYSE:ABT	Health Care
US		Chevron Corp NYSE:CVX	Energy
US		Occidental Petroleum Corp NYSE:OXY	Energy
US		Matrix Service Co NASDAQ:MTRX	Construction
US		Automatic Data Processing Inc NASDAQ:ADP	Technology
US		Qualcomm Inc NASDAQ:QCOM	Semiconductors
US		Ambarella Inc NASDAQ:AMBA	Semiconductors

Add Price Alert

Price Target:

Last Price: 41350 VND

We'll email you a reminder when the closing price reaches USD.

If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.

Peter Lynch

Track and Analyze Performance

Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.

Continuous Learning and Adaptation

Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.

Boost Decision Confidence

With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.

Why create notes?

Back

Delete Note

Do you really want to delete this note?
This action cannot be undone.

Remove price alert for reaching

Delete

Cancel

IMP Alert

Imexpharm Corp

41350

-50 (-0.12%)

52 Week Range	24 572.8953 97 000
Price Target

We'll email you a reminder when the closing price reaches VND.

Save Alert

Choose the stock you wish to monitor with a price alert.

	Fubotv Inc NYSE:FUBO	US
	Bank of America Corp NYSE:BAC	US
	Palantir Technologies Inc NYSE:PLTR	US
C	C3.ai Inc NYSE:AI	US
	Uber Technologies Inc NYSE:UBER	US
	NIO Inc NYSE:NIO	CN
	Fluor Corp NYSE:FLR	US
	Jacobs Engineering Group Inc NYSE:J	US
	TopBuild Corp NYSE:BLD	US
	Abbott Laboratories NYSE:ABT	US
	Chevron Corp NYSE:CVX	US
	Occidental Petroleum Corp NYSE:OXY	US
	Matrix Service Co NASDAQ:MTRX	US
	Automatic Data Processing Inc NASDAQ:ADP	US
	Qualcomm Inc NASDAQ:QCOM	US
	Ambarella Inc NASDAQ:AMBA	US

Delete Alert

This alert will be permanently deleted.

Remove note

Delete

Cancel

Ask me anything about

Imexpharm Corp

What unique competitive advantages
does Imexpharm Corp hold over its rivals?

What risks and challenges
does Imexpharm Corp face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Provide an overview of the primary business activities
of Imexpharm Corp.

What unique competitive advantages
does Imexpharm Corp hold over its rivals?

What risks and challenges
does Imexpharm Corp face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Imexpharm Corp.

Provide P/S
for Imexpharm Corp.

Provide P/E
for Imexpharm Corp.

Provide P/OCF
for Imexpharm Corp.

Provide P/FCFE
for Imexpharm Corp.

Provide P/B
for Imexpharm Corp.

Provide EV/S
for Imexpharm Corp.

Provide EV/GP
for Imexpharm Corp.

Provide EV/EBITDA
for Imexpharm Corp.

Provide EV/EBIT
for Imexpharm Corp.

Provide EV/OCF
for Imexpharm Corp.

Provide EV/FCFF
for Imexpharm Corp.

Provide EV/IC
for Imexpharm Corp.

Show me price targets
for Imexpharm Corp made by professional analysts.

What are the Revenue projections
for Imexpharm Corp?

How accurate were the past Revenue estimates
for Imexpharm Corp?

What are the Net Income projections
for Imexpharm Corp?

How accurate were the past Net Income estimates
for Imexpharm Corp?

What are the EPS projections
for Imexpharm Corp?

How accurate were the past EPS estimates
for Imexpharm Corp?

What are the EBIT projections
for Imexpharm Corp?

How accurate were the past EBIT estimates
for Imexpharm Corp?

Compare the revenue forecasts
for Imexpharm Corp with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Imexpharm Corp and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Imexpharm Corp against its competitors.

Analyze the profit margins
(gross, operating, and net) of Imexpharm Corp compared to its peers.

Compare the P/E ratios
of Imexpharm Corp against its peers.

Discuss the investment returns and shareholder value creation
comparing Imexpharm Corp with its peers.

Analyze the financial leverage
of Imexpharm Corp compared to its main competitors.

Show all profitability ratios
for Imexpharm Corp.

Provide ROE
for Imexpharm Corp.

Provide ROA
for Imexpharm Corp.

Provide ROIC
for Imexpharm Corp.

Provide ROCE
for Imexpharm Corp.

Provide Gross Margin
for Imexpharm Corp.

Provide Operating Margin
for Imexpharm Corp.

Provide Net Margin
for Imexpharm Corp.

Provide FCF Margin
for Imexpharm Corp.

Show all solvency ratios
for Imexpharm Corp.

Provide D/E Ratio
for Imexpharm Corp.

Provide D/A Ratio
for Imexpharm Corp.

Provide Interest Coverage Ratio
for Imexpharm Corp.

Provide Altman Z-Score Ratio
for Imexpharm Corp.

Provide Quick Ratio
for Imexpharm Corp.

Provide Current Ratio
for Imexpharm Corp.

Provide Cash Ratio
for Imexpharm Corp.

What is the historical Revenue growth
over the last 5 years for Imexpharm Corp?

What is the historical Net Income growth
over the last 5 years for Imexpharm Corp?

What is the current Free Cash Flow
of Imexpharm Corp?

Discuss the annual earnings per share (EPS)
trend over the past five years for Imexpharm Corp.

EV/EBITDA
Enterprise Value to EBITDA

14.1

Current

5.5

Median

13.3

Industry

Higher than median

Higher than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA

14.1

Enterprise Value

6.2T VND

EBITDA

441.1B VND

All Countries

Forward Multiples

			Market Cap	EV/EBITDA
VN	I	Imexpharm Corp VN:IMP	6.4T VND	14.1
JP	N	Nichi-Iko Pharmaceutical Co Ltd TSE:4541	776 550.9T JPY	-5 459 134.4
US		Eli Lilly and Co NYSE:LLY	710.5B USD	45.7
UK		Dechra Pharmaceuticals PLC LSE:DPH	440.4B GBP	3 846.3
DK		Novo Nordisk A/S CSE:NOVO B	3.3T DKK	24.3
US		Johnson & Johnson NYSE:JNJ	373.5B USD	12.3
US		Merck & Co Inc NYSE:MRK	251.1B USD	10.5
CH		Roche Holding AG SIX:ROG	202.7B CHF	9.9
CH		Novartis AG SIX:NOVN	183.3B CHF	10.1
UK		AstraZeneca PLC LSE:AZN	162.4B GBP	169.4
IE	E	Endo International PLC LSE:0Y5F	146B USD	234.4

				EBITDA Growth
VN	I	Imexpharm Corp VN:IMP	Average EV/EBITDA: 437.7 14.1	N/A
JP	N	Nichi-Iko Pharmaceutical Co Ltd TSE:4541	Negative Multiple: -5 459 134.4	N/A
US		Eli Lilly and Co NYSE:LLY	45.7	195%
UK		Dechra Pharmaceuticals PLC LSE:DPH	3 846.3	151%
DK		Novo Nordisk A/S CSE:NOVO B	24.3	84%
US		Johnson & Johnson NYSE:JNJ	12.3	14%
US		Merck & Co Inc NYSE:MRK	10.5	331%
CH		Roche Holding AG SIX:ROG	9.9	23%
CH		Novartis AG SIX:NOVN	10.1	8%
UK		AstraZeneca PLC LSE:AZN	169.4	64%
IE	E	Endo International PLC LSE:0Y5F	234.4	N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward

EV/EBITDA

11.9

2-Years Forward

EV/EBITDA

10.6

3-Years Forward

EV/EBITDA

N/A

Imexpharm Corp
VN:IMP

EV/EBITDA
Enterprise Value to EBITDA

EV/EBITDA Forward Multiples

See Also

Company

Help

Tools

Stocks

Imexpharm Corp VN:IMP

EV/EBITDA Enterprise Value to EBITDA

EV/EBITDA Forward Multiples

See Also

Company

Help

Tools

Stocks

Imexpharm Corp
VN:IMP

EV/EBITDA
Enterprise Value to EBITDA